OTCMKTS:BAYRY - Bayer Aktiengesellschaft Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.18 (-1.17%)

This chart shows the closing price for BAYRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bayer Aktiengesellschaft Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BAYRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAYRY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 16 analysts offering 12 month price targets for Bayer Aktiengesellschaft in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.19.

This chart shows the closing price for BAYRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in Bayer Aktiengesellschaft. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/26/2021DZ BankReiterated RatingBuy
5/19/2021Morgan StanleyReiterated RatingOverweight
5/18/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
5/14/2021DZ BankReiterated RatingBuy
5/13/2021Credit Suisse GroupReiterated RatingNeutral
5/13/2021Bryan, Garnier & CoUpgradeSell ➝ Neutral
3/30/2021DZ BankReiterated RatingBuy
3/19/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
3/11/2021Societe GeneraleReiterated RatingHold
3/4/2021Berenberg BankReiterated RatingBuy
3/1/2021Morgan StanleyReiterated RatingOverweight
3/1/2021DZ BankReiterated RatingBuy
2/26/2021Credit Suisse GroupReiterated RatingNeutral
2/10/2021BarclaysReiterated RatingEqual Weight
2/4/2021DZ BankReiterated RatingBuy
1/27/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
1/20/2021Credit Suisse GroupReiterated RatingNeutral
1/8/2021Morgan StanleyReiterated RatingOverweight
1/6/2021Nord/LBReiterated RatingBuy
11/6/2020Morgan StanleyReiterated RatingOverweight
11/5/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
11/5/2020JPMorgan Chase & Co.Reiterated RatingNeutral
11/4/2020Credit Suisse GroupReiterated RatingNeutral
10/21/2020Morgan StanleyReiterated RatingOverweight
10/13/2020BarclaysDowngradeOverweight ➝ Equal Weight
10/5/2020UBS GroupReiterated RatingBuy
10/2/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
10/1/2020Bryan, Garnier & CoDowngradeNeutral ➝ Sell
10/1/2020CitigroupDowngradeBuy ➝ Neutral
10/1/2020HSBCDowngradeBuy ➝ Hold
10/1/2020CommerzbankDowngradeBuy ➝ Hold
9/14/2020Morgan StanleyReiterated RatingOverweight
9/9/2020BMO Capital MarketsInitiated CoverageMarket Perform
9/3/2020Credit Suisse GroupInitiated CoverageNeutral
8/11/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
8/10/2020Morgan StanleyReiterated RatingOverweight
6/26/2020JPMorgan Chase & Co.Reiterated RatingNeutral
6/26/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
6/25/2020Morgan StanleyReiterated RatingOverweight
6/25/2020HSBCUpgradeHold ➝ Buy
6/16/2020CommerzbankUpgradeHold ➝ Buy
4/22/2020Morgan StanleyReiterated RatingOverweight
3/4/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
12/17/2019Berenberg BankUpgradeHold ➝ Buy
8/16/2019Bank of AmericaUpgradeNeutral ➝ Buy
4/1/2019Berenberg BankInitiated CoverageBuy ➝ Hold
3/31/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
3/28/2019Bryan, Garnier & CoDowngradeNeutral ➝ Sell
3/25/2019Bank of AmericaReiterated RatingBuy ➝ Neutral
1/2/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
9/20/2018CitigroupUpgradeNeutral ➝ Buy
8/21/2018Berenberg BankUpgradeHold ➝ Buy
8/15/2018Jefferies Financial GroupDowngradeBuy ➝ Hold
8/13/2018JPMorgan Chase & Co.Reiterated RatingBuy
5/17/2018DZ BankReiterated RatingBuy
9/25/2017BNP ParibasUpgradeNeutral ➝ Outperform
7/3/2017Berenberg BankDowngradeBuy ➝ Hold
2/24/2017Sanford C. BernsteinReiterated RatingOutperform
1/4/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
12/19/2016Jefferies Financial GroupUpgradeHold ➝ Buy
12/7/2016UBS GroupUpgradeNeutral ➝ Buy
9/15/2016Sanford C. BernsteinReiterated RatingBuy
9/14/2016The Goldman Sachs GroupReiterated RatingBuy
8/25/2016CitigroupUpgradeNeutral ➝ Buy
(Data available from 6/23/2016 forward)
Bayer Aktiengesellschaft logo
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Read More

Today's Range

Now: $15.19
Low: $15.15
High: $15.27

50 Day Range

MA: $16.34
Low: $15.19
High: $17.32

52 Week Range

Now: $15.19
Low: $11.65
High: $21.05


377,756 shs

Average Volume

444,392 shs

Market Capitalization

$56.66 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Bayer Aktiengesellschaft?

The following Wall Street analysts have issued reports on Bayer Aktiengesellschaft in the last twelve months: AlphaValue, Barclays PLC, Berenberg Bank, BMO Capital Markets, Bryan, Garnier & Co, Citigroup Inc., Commerzbank AG, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, DZ Bank AG, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Nord/LB, Societe Generale, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for BAYRY.

What is the current price target for Bayer Aktiengesellschaft?

0 Wall Street analysts have set twelve-month price targets for Bayer Aktiengesellschaft in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Bayer Aktiengesellschaft in the next year.
View the latest price targets for BAYRY.

What is the current consensus analyst rating for Bayer Aktiengesellschaft?

Bayer Aktiengesellschaft currently has 8 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BAYRY will outperform the market and that investors should add to their positions of Bayer Aktiengesellschaft.
View the latest ratings for BAYRY.

What other companies compete with Bayer Aktiengesellschaft?

How do I contact Bayer Aktiengesellschaft's investor relations team?

Bayer Aktiengesellschaft's physical mailing address is Kaiser-Wilhelm-Allee 1, Leverkusen 2M, 51368. The company's listed phone number is 49-21-4-30-1 and its investor relations email address is [email protected] The official website for Bayer Aktiengesellschaft is www.bayer.com.